Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company developing and commercializing treatments for neurological and rare diseases. Its commercial products are NUPLAZID (pimavanserin), approved in the United States for hallucinations and delusions associated with Parkinson’s disease psychosis, and… From the company’s description.
Over the twelve months to Sep 30, 2026, Acadia Pharmaceuticals Inc. reported revenue of $1.20B, up 14.8% from a year earlier, and net income of $362.23M. Its operating margin was 10.2%, and operations generated $97.53M in cash. In fiscal 2025, it reported revenue of $1.07B, up 11.9% from fiscal 2024, and net income of $391.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Acadia Pharmaceuticals Inc. does
In the company’s own words
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company developing and commercializing treatments for neurological and rare diseases. Its commercial products are NUPLAZID (pimavanserin), approved in the United States for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), approved for Rett syndrome; DAYBUE STIX is a powder formulation for oral solution. Acadia also develops candidates for conditions including Alzheimer’s disease psychosis, Lewy body dementia psychosis, major depressive disorder, essential tremor and other neurological and rare diseases. The company’s business is organized around neurological disease and rare disease franchises, with NUPLAZID anchoring the former and DAYBUE the latter. Net product sales from the two products totaled $1.0715 billion in fiscal 2025. Acadia discovered and developed pimavanserin and acquired trofinetide rights from Neuren Pharmaceuticals, expanding those rights globally in 2023. Its brands include Acadia, NUPLAZID and DAYBUE. Its website is www.acadia.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1070494
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Acadia Pharmaceuticals Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Acadia Pharmaceuticals Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Acadia Pharmaceuticals Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Acadia Pharmaceuticals Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Acadia Pharmaceuticals Inc.'s last four quarterly filings that the numbers alone won't show?”